-
The growth of investment and financing in the medical and health sector has slowed down, but these areas will still receive attention
Time of Update: 2022-08-15
2 billion yuan According to statistics, in the first half of 2022, there have been 632 investment and financing events in the medical and health sector nationwide, and the disclosed investment and financing amount is 115.
-
The development of traditional Chinese medicine continues to improve, and the pharmaceutical equipment of traditional Chinese medicine is constantly changing to "intelligent manufacturing"!
Time of Update: 2022-08-15
It will help more and more enterprises to achieve more efficient production With the development and application of new technologies such as the Internet of Everything, big data, and artificial intelligence, the positive shift to "intelligent manufacturing" brings more imagination to the traditional Chinese medicine industry.
-
The number of license outs continues to grow, and multinational pharmaceutical companies become a great help for domestic innovative drugs to go overseas
Time of Update: 2022-08-15
Research, development, manufacturing and commercialization outside of China (China includes Mainland China, Hong Kong, Macau and Taiwan) For example, on August 5, Kelun Pharmaceutical announced that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 2022.
-
The number of medical representatives is expected to decrease by more than 2 million, and the transformation is imminent
Time of Update: 2022-08-15
It is necessary to return to academic promotion and continuously improve their professional capabilities in order to continue to face competition and seize new opportunities The industry believes that the medical representatives who choose to remain will face greater pressure, and the transformation is imminent.
-
The pharmaceutical industry has set off a wave of AI research and development, and it will also have great prospects in the pharmaceutical field
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] With the help of AI pharmaceuticals, it can improve the speed of new drug research and development and reduce costs, and help pharmaceutical companies to spee
-
The development of traditional Chinese medicine welcomes the policy "bonus period", and the industry recommends paying attention to these two main investment lines
Time of Update: 2022-08-15
. Traditional Chinese medicine welcomes the "bonus period" of the policy, and the industry recommends paying attention to two main lines (Source: Pharmaceutical Network) For example, on July 14, Dong'e Ejiao issued an announcement on the pre-increase in the first half of 2022, and the net profit is expected to be 270 million yuan to 3.
-
Changes in the traditional Chinese medicine sector, and many stocks such as Teyi Pharmaceutical and Essence Pharmaceuticals rose
Time of Update: 2022-08-15
followed suit [Pharmaceutical Network Pharmaceutical Stock Market] According to news on June 6, the traditional Chinese medicine sector moved up.
83%; the net profit attributable to shareholders of the listed company was about 127 million yuan, a year-on-year increase of 189.
-
In the past week, many pharmaceutical companies have been rated as "buy" by institutions
Time of Update: 2022-08-15
14 yuan Capital Securities recently gave Kangchen Pharmaceutical a buy rating, and the current share price is 25.
-
Affected by favorable policies, traditional Chinese medicine may become the main line of investment in the second half of the year
Time of Update: 2022-08-15
It is worth noting that the industry as a whole continues to Under the positive development, the traditional Chinese medicine sector has also significantly outperformed the pharmaceutical sector in the past year and a half, with a cumulative increase of over 26% (data source: WIND, data from January 1, 2021 to June 30, 2022) .
-
Intensified competition in the industry, local pharmaceutical companies have begun to build production bases
Time of Update: 2022-08-15
billion target According to the plan, by 2030, Mindray Longhua Base will carry more than 60% of the production capacity of the group's supply chain, and cooperate with Mindray Medical Shenzhen Guangming Base to form a two-wheel drive pattern, leading the total output value of Mindray Medical Shenzhen's manufacturing sector to exceed 1,000 in 2030.
-
The research and development of new Chinese medicines has entered a period of rapid development, and these pain points need to be solved urgently
Time of Update: 2022-08-15
With the promotion of a series of policies to encourage and support the development of traditional Chinese medicine, such as the "Guiding Opinions on Inheriting and Innovative Development", the ability of traditional Chinese medicine to inherit and innovate has been significantly enhanced, and the number of applications for clinical trials of new Chinese medicines and new drug marketing authorization applications has also increased year by year .
-
Overseas markets have become new drivers of growth, and pharmaceutical equipment companies have high enthusiasm for development
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] Recently, Chutian Technology, a leading domestic pharmaceutical equipment company, mentioned in an investigation that the company's headquarters plans to double the target of new orders for export business this year compared with 2021, and plans to achieve export business revenue around 2025 about 50% of total revenue .
-
2 Successful IPO registration of pharmaceutical companies: high-end preparations and high-end medical equipment enter the fast lane
Time of Update: 2022-08-15
34 million shares in an initial public offering and raise 600 million yuan, which will be mainly used for the preparation production complex building and related supporting facilities projects, high-end generic drugs and improved new drug research and development projects and supplementary Liquidity According to the prospectus of Xuantai Pharmaceuticals, Xuantai Pharmaceuticals plans to issue 45.
-
Switzerland's revised organ transplant law allows those who do not refuse to be considered organ donors
Time of Update: 2022-08-15
(Headquarters reporter Yi Xin) On May 15, local time, Switzerland held a referendum on three proposals, namely, the revision of the "Organ Transplantation Law", the revision of the "Film Law" and the increase of funding for the European Border Agency, all of which were passed with a high approval rate .
-
The traditional Chinese medicine ETF, which closely tracks the CSI Traditional Chinese Medicine Index, has officially opened for listing and trading!
Time of Update: 2022-08-15
. In addition, in recent years, the relevant favorable policies from the state to the local government have also supported the development of traditional Chinese medicine, and the previous overall planning outline has been converted into more specific development rules, including medical insurance payment, drug review and approval, talent training, etc.
-
Changes in the pharmaceutical sector, Xinhua Pharmaceutical, Yuheng Pharmaceutical and other stocks closed at the daily limit
Time of Update: 2022-08-15
Analysis believes that the stock's daily limit is related to these two drugs The company's main business is the production and sales of Chinese and Western medicine injections.
-
The "involution" of generic drugs has intensified, and innovative drugs will bring a blue ocean of development to pharmaceutical companies
Time of Update: 2022-08-15
. On July 15, Sihuan Pharmaceutical announced that the company intends to propose the sale of some or all of its generic drugs and other non-core traditional medicine businesses that have not met the company's performance expectations or are not in line with the company's long-term strategic goals due to changes in the pharmaceutical industry.
-
Behind the accelerated withdrawal of Chinese patent medicines from medical insurance, what should Chinese medicine companies do?
Time of Update: 2022-08-15
In addition, compared with proprietary Chinese medicines, the industry generally believes that Chinese herbal decoction pieces and formula granules are less pressured by medical insurance to control costs and have growth potential .
-
The pharmaceutical industry is favored by institutions, and this pharmaceutical company has been investigated by hundreds of institutions
Time of Update: 2022-08-15
The types of institutions are QFII, insurance companies, others, fund companies, overseas institutions, securities companies, Sunshine Private Equity For example, Huadong Medicine released a record form of investor relations activities on July 11, and the company received 134 institutional surveys on July 8, 2022.
-
The speed of generic drugs "going overseas" has intensified, and the news of foreign approval of products continues
Time of Update: 2022-08-15
After this approval, according to the US CGT (competitive generic therapy) Act, Hengrui Medicine Iodixanol injection will obtain a 180-day market exclusivity period, and is expected to become a product of Hengrui Medicine with overseas sales of over US$100 million At the end of May this year, Hengrui Medicine's iodixanol was approved in the ANDA (generic drug listing) application in the United States.
